Chau T. Dang, MD, Discusses the APHINITY Trial
The breast cancer expert spoke about the results presented in the trial, noting the benefit seen with longer follow-up.
Related Articles
NeoCOAST-2 Data Show Pathologic Responses Across Various Combos in NSCLC
In particular, dato-DXd plus durvalumab and chemotherapy produced the highest pCR and mPR rates in the phase 2 NeoCOAST-2 trial.
Medical Oncology at Hope Regional Cancer Center
Join Our Thriving Oncology Community in Panama City, Florida! Are you a medical oncologist seeking a vibrant practice location? Look no further than Panama City,…
Omission of 5-FU From Combo Therapy May Improve Results in Advanced GI Cancers
The use of 5-fluorouracil decreased toxicity and possible savings in first-line advanced gastrointestinal cancers.
Liso-cel Shows Responses Across High-Risk Relapsed/Refractory CLL Subgroups
Earlier use of liso-cel may improve responses in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Subcutaneous Daratumumab Combo Improves MRD-Negative Status in NDMM
Data from the PERSEUS trial support the benefit of D-VRd and DR maintenance as a standard of care in transplant-eligible newly diagnosed multiple myeloma.
Improving Quality of Life in Cancer With Physical Medicine & Rehabilitation
Jessica Cheng, MD, highlights how physical medicine and rehabilitation may help optimize function and performance status in patients with cancer.
Deep Learning Models Expedite Biomarker Discovery, Detection in Lung Cancer
Investigators showcased feasibility of combining pathology findings with deep learning artificial intelligence to speed up biomarker detection and discovery for patients with lung cancer.
Liso-cel Shows Responses Across High-Risk Relapsed/Refractory CLL Subgroups
Earlier use of liso-cel may improve responses in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Adverse Event Management with BCMA Therapy
Ellen Marin, PA-C, provides an overview of adverse effects associated with BCMA-directed bispecific therapy in multiple myeloma.